The purpose of this study is to evaluate the safety and tolerance of a new intravenous diagnostic agent , SeeMore or EVP 1001-1, in patients with Cardiovascular Disease. The initial phase of this study, NCT01989195 enrolling a total of 6 patients, has been closed. This second phase adds 10 patients in a safety cohort and 60 additional patients for a total of 70 patients.